-
公开(公告)号：US20150374723A1
公开(公告)日：2015-12-31
申请号：US14831220
申请日：2015-08-20
Inventor： Brian Agnew , David Graham , Upinder Singh , Scott Grecian
IPC: A61K31/655 , A61K38/21 , A61K31/7088 , A61K45/06
CPC classification number: A61K31/655 , A61K31/7024 , A61K31/7088 , A61K38/212 , A61K38/215 , A61K45/06 , A61K2300/00
Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
Abstract translation: 提供了使用叠氮化物修饰的生物分子如脂肪酸，碳水化合物和脂质来治疗植物，昆虫或感染病毒的动物或抑制病毒如人类免疫缺陷病毒的感染性的方法。 还提供了用叠氮化物修饰的生物分子如脂肪酸，碳水化合物或类异戊二烯脂质来标记病毒（例如人类免疫缺陷病毒）的方法。 此外，提供了利用叠氮化物修饰的生物分子如脂肪酸，碳水化合物或类异戊二烯脂质体内追踪病毒的方法。 叠氮化物修饰的生物分子可以与药学上可接受的赋形剂组合以产生药物组合物，任选地含有另一种抗病毒剂和/或递送剂，例如脂质体。
-
公开(公告)号：US20180092932A1
公开(公告)日：2018-04-05
申请号：US15834639
申请日：2017-12-07
Inventor： Brian Agnew , David Graham , Upinder Singh , Scott Grecian
IPC: A61K31/655 , A61K31/7024 , A61K45/06 , A61K38/21 , A61K31/7088
CPC classification number: A61K31/655 , A61K31/7024 , A61K31/7088 , A61K38/212 , A61K38/215 , A61K45/06 , A61K2300/00
Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
公开(公告)号：US09890361B2
公开(公告)日：2018-02-13
申请号：US14374404
申请日：2013-01-25
Inventor： Brian Agnew , David Graham
CPC classification number: C12N7/00 , A61K39/00 , A61K48/00 , C12N2740/16034 , C12N2740/16045 , C12N2740/16051 , C12N2810/10
Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
Patent Agency Ranking
公开(公告)号：US09855287B2
公开(公告)日：2018-01-02
申请号：US14831220
申请日：2015-08-20
Inventor： Brian Agnew , David Graham , Upinder Singh , Scott Grecian
IPC: A61K31/655 , A61K31/7024 , A61K45/06 , A61K31/7088 , A61K38/21
CPC classification number: A61K31/655 , A61K31/7024 , A61K31/7088 , A61K38/212 , A61K38/215 , A61K45/06 , A61K2300/00
Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
公开(公告)号：US11732244B2
公开(公告)日：2023-08-22
申请号：US17021163
申请日：2020-09-15
Inventor： Brian Agnew , David Graham
CPC classification number: C12N7/00 , A61K39/00 , A61K48/00 , C12N2740/16034 , C12N2740/16045 , C12N2740/16051 , C12N2810/10
Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
公开(公告)号：US10808228B2
公开(公告)日：2020-10-20
申请号：US15865713
申请日：2018-01-09
Inventor： Brian Agnew , David Graham
Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
公开(公告)号：US20180171306A1
公开(公告)日：2018-06-21
申请号：US15865713
申请日：2018-01-09
Inventor： Brian Agnew , David Graham
Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
公开(公告)号：US20150037288A1
公开(公告)日：2015-02-05
申请号：US14374404
申请日：2013-01-25
Inventor： Brian Agnew , David Graham
IPC: C12N7/00
CPC classification number: C12N7/00 , A61K39/00 , A61K48/00 , C12N2740/16034 , C12N2740/16045 , C12N2740/16051 , C12N2810/10
Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.044 seconds)
